Mesoblast Limited
Biotechnology, 505 5th Ave, Melbourne, New York, 10017, United States, 51-200 Employees
Phone Number: 61*********
Who is MESOBLAST LIMITED
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medica...
Read More
-
Headquarters: 505 5th Ave, Melbourne, New York, 10017, United States
-
Date Founded: 2004
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from MESOBLAST LIMITED
Mesoblast Limited Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Mesoblast Limited
Answer: Mesoblast Limited's headquarters are located at 505 5th Ave, Melbourne, New York, 10017, United States
Answer: Mesoblast Limited's phone number is 61*********
Answer: Mesoblast Limited's official website is https://mesoblast.com
Answer: Mesoblast Limited's revenue is $25 Million to $50 Million
Answer: Mesoblast Limited's SIC: 2834
Answer: Mesoblast Limited's NAICS: 325412
Answer: Mesoblast Limited has 51-200 employees
Answer: Mesoblast Limited is in Biotechnology
Answer: Mesoblast Limited contact info: Phone number: 61********* Website: https://mesoblast.com
Answer: Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: RYONCILTM (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection REVASCOR for advanced chronic heart failure, and MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Companys proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblasts approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month